Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: The PROSE study population

Psoriasis

Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

J Eur Acad Dermatol Venereol.

Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, Szepietowski JC, Perrot JL, Cuccia A, Rissler M, Gathmann S, Sieder C, Orsenigo R, Jagiello P, Bachhuber T

doi: 10.1111/jdv.16632.

Psoriasis

Efficacy of Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis by Baseline Demographics, Disease Characteristics and Prior Biologic Therapy: An Integrated Analysis of the Phase III UltIMMa-1 and UltIMMa-2 Studies

J Eur Acad Dermatol Venereol.

Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, Photowala H, Longcore M, Zhan T, Foley P

doi: 10.1111/jdv.16521.

Psoriasis

Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment: Results from a randomised, active comparator-controlled phase 3b trial (POLARIS)

Br J Dermatol.

Thaҫi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K

doi: 10.1111/bjd.18696.

Psoriasis

Linkage between patients' characteristics and prescribed systemic treatments for Psoriasis: a semantic connectivity map analysis of the Swiss SDNTT registry

J Eur Acad Dermatol Venereol.

Cazzaniga S, Anzengruber F, Augustin M, Boehncke WH, Borradori L, Conrad C, Cozzio A, Djamei V, French LE, Gilliet M, Häusermann P, Heidemeyer K, Itin P, Kolios AGA, Laffitte E, Maul JT, Mainetti C, Naldi L, Navarini AA, Rustenbach SJ, Simon D, Sorbe C, Streit M, Yawalkar N

doi: 10.1111/jdv.15983.

Psoriasis

Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics

Eur J Dermatol

Offidani A, Radi G, Bianchi L, Cannavò SP, Conti A, Gesuita R, Salaffi F, Talamonti M, Campanati A

doi: 10.1684/ejd.2021.4121

PsoriasisPsoriatic Arthritis

Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study)

J Eur Acad Dermatol Venereol.

Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U

doi: 10.1111/jdv.14878.

Further Publications Dermatology

Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: Patient perspective data from the PROSE study

J Eur Acad Dermatol Venereol

da Silva N, Sommer R, Ortmann CE, Jagiello P, Bachhuber T, Augustin M

doi: 10.1111/jdv.17525

Psoriasis

Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.

Am J Clin Dermatol.

Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M

doi: 10.1007/s40257-017-0274-0.

COMMENTED

Psoriasis

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Lancet.

Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C

doi: 10.1016/S0140-6736(19)30952-3.

Related content

Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

Efficacy of Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis by Baseline Demographics, Disease Characteristics and Prior Biologic Therapy: An Integrated Analysis of the Phase III UltIMMa-1 and UltIMMa-2 Studies

Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment: Results from a randomised, active comparator-controlled phase 3b trial (POLARIS)

Linkage between patients' characteristics and prescribed systemic treatments for Psoriasis: a semantic connectivity map analysis of the Swiss SDNTT registry

Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics

Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study)

Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: Patient perspective data from the PROSE study

Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial